State-of-the-Art in Chronic Obstructive Pulmonary Disease (COPD)
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 4790
Special Issue Editor
Interests: asthma; biological agents; inhaler agents
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear colleagues,
Chronic obstructive pulmonary disease (COPD) is a respiratory disease with significant contributions to morbidity and mortality worldwide and is a known risk factor of lung cancer. Despite the enormous and increasing social–economic burden associated with COPD, this illness is preventable and treatable. The complex and heterogeneous nature of COPD has prompted us to design a novel COPD therapeutic policy that addresses lung function severity, symptoms, serum biomarkers, phenotypes, and comorbidities. The clinical phenotypes should comprise a survey of frequent exacerbators, chronic bronchitis, ACOS, and bronchiectasis–COPD overlay syndrome. The treatment of patients with COPD in a more personalized way must address diverse aspects not only related to the disease, but also to its comorbidities, and current schemes do not offer such personalized medical treatment. Comorbidity evaluation and management were all mentioned in each clinical practice guideline (CPG), the comorbidities including systemic inflammation, osteoporosis, musculoskeletal defect, cardiovascular disorders, gastrointestinal dysfunction, depression, metabolic disorders, and obstructive sleep apnea. Additionally, the variability of the clinical presentation interacts with comorbidities to form a complex clinical scenario for clinicians. Different comorbidities have different evaluation and management policies. Consequently, the CPG or consensus should be reached over a practical approach for combining comorbidities and disease presentation markers in the therapeutic algorithm, in order to improve the quality of clinical care.
Dr. Shih-Lung Cheng
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COPD
- individualized approach
- precision therapy
